192 related articles for article (PubMed ID: 18085684)
41. Higher incidence of syndrome of inappropriate antidiuretic hormone secretion during induction chemotherapy of acute lymphoblastic leukemia in indian children.
Seetharam S; Thankamony P; Gopakumar KG; Krishna KMJ
Indian J Cancer; 2019; 56(4):320-324. PubMed ID: 31607700
[TBL] [Abstract][Full Text] [Related]
42. Identification of a less toxic vinca alkaloid derivative for use as a chemotherapeutic agent, based on in silico structural insights and metabolic interactions with CYP3A4 and CYP3A5.
Saba N; Seal A
J Mol Model; 2018 Mar; 24(4):82. PubMed ID: 29502215
[TBL] [Abstract][Full Text] [Related]
43. Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy.
Moudgil SS; Riggs JE
Ann Pharmacother; 2000 Oct; 34(10):1136-8. PubMed ID: 11054980
[TBL] [Abstract][Full Text] [Related]
44. Hemolytic uremic syndrome secondary to the treatment of acute lymphoblastic leukemia.
Kanchi H; Webb NJ; Eden OB
J Pediatr Hematol Oncol; 2000; 22(5):483-4. PubMed ID: 11037870
[No Abstract] [Full Text] [Related]
45. Acute sixth-nerve palsy after vincristine therapy.
Lash SC; Williams CP; Marsh CS; Crithchley C; Hodgkins PR; Mackie EJ
J AAPOS; 2004 Feb; 8(1):67-8. PubMed ID: 14970803
[TBL] [Abstract][Full Text] [Related]
46. Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia.
Li L; Sajdyk T; Smith EML; Chang CW; Li C; Ho RH; Hutchinson R; Wells E; Skiles JL; Winick N; Martin PL; Renbarger JL
Clin Pharmacol Ther; 2019 Jun; 105(6):1421-1428. PubMed ID: 30506673
[TBL] [Abstract][Full Text] [Related]
47. Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy.
Sawaki A; Miyazaki K; Yamaguchi M; Takeuchi T; Kobayashi K; Imai H; Tawara I; Ono R; Nosaka T; Katayama N
Int J Hematol; 2020 May; 111(5):686-691. PubMed ID: 31993939
[TBL] [Abstract][Full Text] [Related]
48. Pediatric Oncology Patients With Vincristine-Induced Recurrent Laryngeal Nerve Palsy: Two Case Reports and a Brief Review of Literature.
Tay SY; Foster J; Heczey A; Sitton M
Ear Nose Throat J; 2021 Dec; 100(10):NP459-NP463. PubMed ID: 32425060
[TBL] [Abstract][Full Text] [Related]
49. Acute and sub-acute neurological toxicity in children treated for acute lymphoblastic leukemia.
Millan NC; Pastrana A; Guitter MR; Zubizarreta PA; Monges MS; Felice MS
Leuk Res; 2018 Feb; 65():86-93. PubMed ID: 29328996
[TBL] [Abstract][Full Text] [Related]
50. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.
Harnicar S; Adel N; Jurcic J
J Oncol Pharm Pract; 2009 Sep; 15(3):175-82. PubMed ID: 19282418
[TBL] [Abstract][Full Text] [Related]
51. Vincristine-induced unilateral ptosis in a child.
Gursel O; Sari E; Altun D; Atay AA; Akin R
Pediatr Neurol; 2009 Dec; 41(6):461-3. PubMed ID: 19931172
[TBL] [Abstract][Full Text] [Related]
52. Severe Vincristine-induced Neuropathic Pain in a CYP3A5 Nonexpressor With Reduced CYP3A4/5 Activity: Case Study.
Bosilkovska M; Ing Lorenzini K; Uppugunduri CR; Desmeules J; Daali Y; Escher M
Clin Ther; 2016 Jan; 38(1):216-20. PubMed ID: 26565076
[TBL] [Abstract][Full Text] [Related]
53. Vocal cord paralysis secondary to vincristine treatment in children: A case series of seven children and literature review.
Godbehere J; Payne J; Thevasagayam R
Clin Otolaryngol; 2021 Sep; 46(5):1114-1118. PubMed ID: 33811799
[No Abstract] [Full Text] [Related]
54. Vincristine-induced neuropathy in childhood ALL (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics.
Jain P; Gulati S; Seth R; Bakhshi S; Toteja GS; Pandey RM
J Child Neurol; 2014 Jul; 29(7):932-7. PubMed ID: 23781018
[TBL] [Abstract][Full Text] [Related]
55. Vincristine toxicity with co-administration of fluconazole during induction therapy for pediatric acute lymphoblastic leukemia.
Smitherman AB; Faircloth CB; Deal A; Troy M; Gold SH
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28333402
[TBL] [Abstract][Full Text] [Related]
56. Genetic factors influencing the development of vincristine-induced neurotoxicity.
Pozzi E; Fumagalli G; Chiorazzi A; Canta A; Cavaletti G
Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):215-226. PubMed ID: 33283553
[No Abstract] [Full Text] [Related]
57. Regarding "Intrathecal vincristine: 3 fatal cases and a review of the literature".
Walter AW
J Pediatr Hematol Oncol; 2010 May; 32(4):336-7. PubMed ID: 20445422
[No Abstract] [Full Text] [Related]
58. Small-fiber neuropathy and pain sensitization in survivors of pediatric acute lymphoblastic leukemia.
Lieber S; Blankenburg M; Apel K; Hirschfeld G; Hernáiz Driever P; Reindl T
Eur J Paediatr Neurol; 2018 May; 22(3):457-469. PubMed ID: 29396168
[TBL] [Abstract][Full Text] [Related]
59. Clinical Analysis of Adverse Drug Reactions between Vincristine and Triazoles in Children with Acute Lymphoblastic Leukemia.
Yang L; Yu L; Chen X; Hu Y; Wang B
Med Sci Monit; 2015 Jun; 21():1656-61. PubMed ID: 26050202
[TBL] [Abstract][Full Text] [Related]
60. [Isolated unilateral cranial nerve palsy during childhood acute lymphoblastic leukemia treatment: What does it mean?].
Saumet L; Haouy S; Daien V; Hillaire-Buys D; Roessler J; Sirvent N
Arch Pediatr; 2016 Apr; 23(4):415-6. PubMed ID: 26968305
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
